Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00003598 · ClinicalTrials.gov registry record · NA
UMCC 9609 Tretinoin in Preventing Cancer of the Cervix in Patients With Cervical Neoplasia
A NA study, sponsored by University of Michigan Rogel Cancer Center.
- Completed
- Registry status
- NA
- Development phase
- 180
- Enrollment target
NCT00003598 is a NA study that has completed, run by University of Michigan Rogel Cancer Center. The registered enrollment target is 180 participants.
The verdict
NCT00003598, a NA study, has completed, sponsored by University of Michigan Rogel Cancer Center.
- COMPLETED
- Registry status
- NA
- Development phase
- 180 participants
- Enrollment target
Study Summary
RATIONALE: Tretinoin may help cervical neoplasia cells develop into normal cervical cells. It is not yet known whether tretinoin is more effective than a placebo in preventing cervical cancer in patients with cervical neoplasia. PURPOSE: Randomized clinical trial to study the effectiveness of tretinoin in preventing cervical neoplasia from developing into cervical cancer.
Interventions
- DRUG tretinoin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 180 participants |
| Start Date | 1999-01 |
| Est. Completion | 2009-11 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00003598
The ClinicalTrials.gov registry entry for NCT00003598 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 180 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Michigan Rogel Cancer Center, which has 292 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which tretinoin is the first listed.
NCT00003598 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00003598 about?
NCT00003598 is a clinical study titled "UMCC 9609 Tretinoin in Preventing Cancer of the Cervix in Patients With Cervical Neoplasia". RATIONALE: Tretinoin may help cervical neoplasia cells develop into normal cervical cells. It is not yet known whether tretinoin is more effective than a placebo in preventing cervical cancer in patients with cervical neoplasia. PURPOSE: Randomized clinical trial to study the effectiveness of treti...
What is the current status of trial NCT00003598?
This trial is currently completed. It is a NA study. The enrollment target is 180 participants. The study started on 1999-01. Estimated completion is 2009-11.
What interventions are being tested in trial NCT00003598?
The interventions under investigation include: tretinoin (DRUG).
Who is sponsoring clinical trial NCT00003598?
This trial is sponsored by University of Michigan Rogel Cancer Center, which has 292 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.